Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study - Saucedo, Jorge F; Angiolillo, Dominick J; DeRaad, Roger; Frelinger, 3rd, Andrew L; Gurbel, Paul A; Costigan, Timothy M; Jakubowski, Joseph A; Ojeh, Clement K; Duvvuru, Suman; Effron, Mark B (Thrombosis and haemostasis, 2013)
Keywords: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Aged; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - metabolism; Blood Platelets - drug effects; Blood Platelets - metabolism; Cell Adhesion Molecules - blood; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Substitution; Female; Genotype; Humans; Male; Microfilament Proteins - blood; Middle Aged; Pharmacogenetics; Phenotype; Phosphoproteins - blood; Piperazines - administration & dosage; Piperazines - adverse effects; Piperazines - metabolism; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - metabolism; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists - administration & dosage; Purinergic P2Y Receptor Antagonists - adverse effects; Purinergic P2Y Receptor Antagonists - metabolism; Receptors, Purinergic P2Y12 - blood; Receptors, Purinergic P2Y12 - drug effects; Thiophenes - administration & dosage; Thiophenes - adverse effects; Thiophenes - metabolism; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - metabolism; Treatment Outcome